Vibliome Therapeutics, LLC, has developed a novel systematic approach that enables the design of small molecule kinase inhibitors with unique selectivity profiles and extraordinary selectivity. 

Pharmaceutical

Vibliome Therapeutics

Robert Goodwin

Doug Werner

Patrick Green

Gary A. Flynn

The Scientific Team at Vibliome Therapeutics is responsible for advancing the design and development of selective small molecule kinase inhibitors. This team provides expert guidance on scientific strategies, oversees medicinal chemistry efforts, and manages research alliances to ensure the creation of innovative therapeutic solutions.

Scientific Team

About

Team members

Other teams at Vibliome Therapeutics

Leadership Team